Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

621
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
621
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

630
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
630
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.7K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.7K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

2.5K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.5K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

746
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
746

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardio-kidney-metabolic overlap in patients with severe heart failure: Data from the HELP-HF registry.

American heart journal·2026
Same author

Beyond Weight and Renal Function: DOAC Plasma Levels Remain the Primary Determinant of Acute Outcomes-A Re-Analysis of the 4Levels Study.

Clinical therapeutics·2026
Same author

Sex differences in patients with advanced heart failure: an analysis of the HELP-HF registry.

ESC heart failure·2026
Same author

Intraprocedural Imaging Strategies for Patent Foramen Ovale Closure: A Real-world Comparison From the PROLONG Registry.

The Canadian journal of cardiology·2026
Same author

A Novel Surgical Technique for Total Knee Arthroplasty Using the Femoral Trochlear Bisector as a New Landmark: Technical Description and Early Clinical Results.

Journal of clinical medicine·2026
Same author

Painless bilateral orbital myositis during a multisystem flare of systemic lupus erythematosus: Case report and focused literature review.

Lupus·2026

Related Experiment Video

Updated: Apr 26, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

12.5K

[Metabolic therapy for heart failure].

Ferdinando Loiacono, Luca Alberti, Ludovica Lauretta

    Recenti Progressi in Medicina
    |July 30, 2014
    PubMed
    Summary

    Heart failure alters metabolism, increasing fat use and decreasing energy production. Shifting to glucose metabolism with drugs like trimetazidine may improve outcomes and reduce mortality in heart failure patients.

    Area of Science:

    • Cardiology
    • Metabolic Medicine
    • Pharmacology

    More Related Videos

    Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
    09:11

    Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

    Published on: September 22, 2014

    11.4K
    Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
    11:51

    Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

    Published on: March 1, 2016

    9.9K

    Related Experiment Videos

    Last Updated: Apr 26, 2026

    Gene Transfer for Ischemic Heart Failure in a Preclinical Model
    07:35

    Gene Transfer for Ischemic Heart Failure in a Preclinical Model

    Published on: May 15, 2011

    12.5K
    Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
    09:11

    Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

    Published on: September 22, 2014

    11.4K
    Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
    11:51

    Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

    Published on: March 1, 2016

    9.9K